Harnessing the power of the human microbiome

whitePaper | January 31, 2023

The first biosimilar approved under the abbreviated pathway established by the Biologics Price Competition and Innovation Act launched in the U.S. in 2015.

whitePaper | October 19, 2022

The Organisation for Economic Co-operation and Development and its member countries have been addressing issues related to biotechnology since 1982.

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

whitePaper | September 27, 2022

Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field.

whitePaper | December 22, 2022

Single-pass tangential flow filtration (SPTFF) technology from Pall Corporation is revolutionizing current and future bioprocessing platforms with its implementations in biotech, vaccine and plasma industries. Its features are protected by a portfolio of patents[1-6].

whitePaper | August 22, 2022

Biosimilar therapies offer more unique approaches to treating patients with serious diseases, such as cancer.